Trump pivots to fast-track psychedelic therapies for mental health

Marie Phelan, an Army Reserve veteran, describes her experience with MDMA-assisted therapy as a profound emotional release that finally allowed her to set down the heavy psychological baggage of her 2003 Iraq deployment. Her recovery reflects a growing shift in how experimental treatments are viewed within the highest levels of government.

President Donald Trump recently signed an executive order designed to accelerate research into psychedelic drugs for mental illness. This directive marks a distinct departure from the administration’s previous, more restrictive stance on controlled substances. The White House now acknowledges that these compounds show clinical potential for treating patients who have found no relief through standard medical protocols.

To facilitate this transition, the administration has issued priority review vouchers to three key developers: Compass Pathways, Usona Institute, and Transcend Therapeutics. These vouchers are intended to expedite the FDA review process for MDMA-like therapies. While this expansion offers a new path for patients struggling with trauma, the rapid shift has also triggered increased scrutiny regarding the long-term safety and overall efficacy of such treatments as they move closer to mainstream healthcare.